Julie Cherrington, Ph.D.

Julie has an extensive background in biotechnology. She currently serves on the Boards of Directors of Elevation Oncology, Syncona Limited, Actym Therapeutics (Chair), Tolremo Therapeutics (Chair) and MycRx (Chair) and previously served on several other Boards of drug development and discovery companies. She has served as a Venture Partner with the venture capital firm, Brandon Capital Partners, since 2022. She previously served as CEO of QUE Oncology, as President and CEO of Arch Oncology, Revitope Oncology, Zenith Epigenetics and Pathway Therapeutics and as President and EVP, R&D of Phenomix Corporation. Earlier in her career, Julie was Vice President of Preclinical and Clinical Research at SUGEN, a Pharmacia/Pfizer company. She began her career at Gilead Sciences, where she held positions of increasing responsibility.

Julie earned a Ph.D. in microbiology and immunology from the University of Minnesota and Stanford University, and a B.S. in biology and an M.S. in microbiology from the University of California, Davis. She completed a postdoctoral fellowship at the University of California, San Francisco.